Teva Pharmaceuticals USA, Inc recalls
20 recalls filed under Teva Pharmaceuticals USA, Inc. The most recent was published September 9, 2026.
-
Class II · last month
Teva Pharmaceuticals USA, Inc traZODone Hydrochloride Tablets, USP, 50 mg recall: Presence of Foreign Tablets/Capsules
Presence of Foreign Tablets/Capsules
-
Class II · 6 months ago
Teva Pharmaceuticals USA, Inc Octreotide Acetate for Injectable Suspension recall: Lack of Assurance of Sterility: Quality system deficiencies identified during
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the…
-
Class II · 6 months ago
Teva Pharmaceuticals USA, Inc Claravis , 10 mg, Packaged as a) 100-count carton recall: Failed Impurities/Degradation Specifications: Out of specification
Failed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin
-
Class II · 6 months ago
Teva Pharmaceuticals USA, Inc Isotretinoin Capsules, USP, 30 mg recall: Superpotent and Subpotent
Superpotent and Subpotent
-
Class II · 6 months ago
Teva Pharmaceuticals USA, Inc Isotretinoin Capsules, USP, 40 mg recall: Superpotent and Subpotent
Superpotent and Subpotent
-
Class II · 6 months ago
Teva Pharmaceuticals USA, Inc Clonidine Transdermal System, USP, 0.3 mg/day recall: CGMP Deviations: use of an unapproved raw material
CGMP Deviations: use of an unapproved raw material
-
Class II · 6 months ago
Teva Pharmaceuticals USA, Inc Clonidine Transdermal System, USP, 0.1 mg/day recall: CGMP Deviations: use of an unapproved raw material
CGMP Deviations: use of an unapproved raw material
-
Class II · 6 months ago
Teva Pharmaceuticals USA, Inc Clonidine Transdermal System, USP, 0.2 mg/day recall: CGMP Deviations: use of an unapproved raw material
CGMP Deviations: use of an unapproved raw material
-
Class II · 7 months ago
Teva Pharmaceuticals USA, Inc Octreotide Acetate for Injectable Suspension recall: Lack of Assurance of Sterility: Quality system deficiencies identified during
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the…
-
Class II · 7 months ago
Teva Pharmaceuticals USA, Inc Octreotide Acetate for Injectable Suspension recall: Lack of Assurance of Sterility: Quality system deficiencies identified during
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the…
-
Class II · 7 months ago
Teva Pharmaceuticals USA, Inc Octreotide Acetate for Injectable Suspension recall: Lack of Assurance of Sterility: Quality system deficiencies identified during
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the…
-
Class II · 8 months ago
Teva Pharmaceuticals USA, Inc Metoprolol Succinate Extended-Release Tablets recall: Failed Dissolution Specifications
Failed Dissolution Specifications
-
Class II · 8 months ago
Teva Pharmaceuticals USA, Inc Metoprolol Succinate Extended-Release Tablets, 200 mg recall: Failed Dissolution Specifications
Failed Dissolution Specifications
-
Class II · 8 months ago
Teva Pharmaceuticals USA, Inc Metoprolol Succinate Extended-Release Tablets, 25 mg recall: Failed Dissolution Specifications
Failed Dissolution Specifications
-
Class II · 8 months ago
Teva Pharmaceuticals USA, Inc Metoprolol Succinate Extended-Release Tablets, 50 mg recall: Failed Dissolution Specifications
Failed Dissolution Specifications
-
Class III · 11 months ago
Teva Pharmaceuticals USA, Inc Carton label: Testosterone Gel 1% recall: Defective Container - A defect in the side-seal which allows leakage
Defective Container - A defect in the side-seal which allows leakage of product.
-
Class II · 12 months ago
Teva Pharmaceuticals USA, Inc Amoxicillin and Clavulanate Potassium for Oral recall: Subpotent drug; Clavulanate Potassium component
Subpotent drug; Clavulanate Potassium component
-
Class II · 12 months ago
Teva Pharmaceuticals USA, Inc Prazosin Hydrochloride, Capsules, USP, 5 mg recall: CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable…
-
Class II · 12 months ago
Teva Pharmaceuticals USA, Inc Prazosin Hydrochloride, Capsules, USP, 1 mg recall: CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable…
-
Class II · 12 months ago
Teva Pharmaceuticals USA, Inc Prazosin Hydrochloride, Capsules, USP, 2 mg recall: CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable…
About this page
Teva Pharmaceuticals USA, Inc appears here because a federal agency named it as the recalling firm or the brand on the label. A recall is not a judgement about everything the company sells — it covers only the lot codes and models listed in each notice.